The consistency of the benefit of SGLT-2 inhibitors on cardiovascular and kidney failure outcomes was investigated in an updated 2021 meta-analysis of all 6 currently available phase 3 trials involving a total of 46,969 participants [21]. Here, SLC5A2 is linked to kidney failure.